About Avadel Pharmaceuticals plc
Who We Are: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Oxybate therapy is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients living with narcolepsy. However, currently approved oxybate products are immediate release formulations requiring two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night. Our current lead drug candidate, LUMRYZTM (sodium oxybate) extended release for oral suspension (formerly known as FT218), applies our proprietary drug delivery technology to allow for a single bedtime dose, eliminating the need to have a forced awakening during the middle of the night and giving patients the chance for an uninterrupted nights sleep. An extended-release medication sounds like a simple innovation, but it is what has been lacking for 20 years and we believe this will be transformative for people with narcolepsy. For more information, please visit www.avadel.com or check out narcolespydisrupts.com.
What We Do: LUMRYZ has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that LUMRYZ may be clinically superior to a formulation of sodium oxybate already approved by the FDA for the same indication.
The FDA granted a tentative approval to LUMRYZ on July 18, 2022. Tentative approval indicates that LUMRYZ has met all required quality, safety, and efficacy standards necessary for approval in the U.S. FDAs final approval decision for LUMRYZ is pending expiration or other disposition of a patent listed in FDAs Orange Book that expires on June 17, 2023. Avadels market research suggests that LUMRYZ has the potential to command a meaningful share of the multi-billion-dollar narcolepsy treatment market.
We are currently taking steps to accelerate the final approval of LUMRYZ earlier than the expiry of the patent in June 2023, however, in either case, we are gearing up for our full launch now. We cant wait to bring an innovative new treatment option to the narcolepsy community.
How We Work: At Avadel, patients are the reason we exist, and our employees are our greatest competitive advantage our secret sauce. The way we work is as important as the results we achieve. Our employees work together as ONE team and live our Values, which is what makes working at Avadel so special and why we will win for patients. Our ONE Team approach fosters a culture based on being relentless for patients, having confidence with humility, being courageous, taking insights to impact, and togetherness. In everything we do, we live the Avadel Values so we can be our best for our patients, our community and each other.
We are seeking team members who have a passion for making a meaningful impact in the lives of patients. We need individuals who will dive in, roll up their sleeves, and join us in our mission to launch LUMRYZ for the narcolepsy community and be part of building and shaping an exciting future together.
Position Summary:
The Product Manager/Sr Product Manager, HCP Marketing will be a critical member of the brand team responsible for launching LUMRYZ for the treatment of narcolepsy. We are looking for a passionate HCP marketer who is equally comfortable developing high-level brand strategies and rolling up their sleeves to implement tactics. S/he will lead the development and implementation of the market access marketing strategies and tactics, as well as, act as the medical marketer within the brand team. This includes any KOL or peer-to-peer strategies and associated tactics. This person will be the primary point of contact for the MSL team. This is a unique opportunity for a dynamic, experienced pharmaceutical marketeer to be a major contributor to an exciting launch in the orphan / rare disease area to help people living with narcolepsy as a lifetime, chronic CNS condition.
Essential Functions:
Market Access Expertise
HCP Peer-to-Peer & KOL Marketing Expertise (physician, NP/PA, pharmacist, etc.)
Agency & Budget Management
Other Key Duties/Responsibilities:
Experience and Qualifications:
Other Competencies and Behaviors:
Avadel is committed to facilitating an open, honest, inclusive, transparent, and productive work environment where we work together as ONE team and ONE culture to be our best for patients, customers, and each other. Avadel is committed to equal employment opportunities and non-discrimination in employment. We believe that all employees and applicants should be treated with courtesy, dignity, and respect. Avadel does not discriminate in employment on the basis of race, color, religion, sex, sexual orientation, national origin, age, disability, genetic information, marital status, ancestry, gender, gender identity, pregnancy, status as a covered veteran, or any other characteristic protected by federal, state, and/or local law. It is our intent to comply with federal, state, and local laws, regulations, and guidelines in our employment practices and in our service to our clients. This policy applies to all terms and conditions of employment including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.
PI206877043
Our free job seeker tools include alerts for new jobs, saving your favorites, optimized job matching, and more! Just enter your email below.